Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc. in metadata) on December 21, 2016. The filing addresses the departure of a senior executive and the execution of a separation agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms related to a separation.
Material Changes
- Executive Departure: Ryan Brenneman ceased serving as Chief Financial Officer on December 19, 2016.
- Separation Agreement: Entered into on December 21, 2016, with an effective date of December 29, 2016.
- Compensation Terms: Subject to a seven-day revocation period, Mr. Brenneman is entitled to four months of base salary and three months of full COBRA premium coverage.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is the seven-day revocation period for the Separation Agreement; if Mr. Brenneman revokes his acceptance, the compensation terms may not apply. The agreement includes a general release in favor of the Company.
Investor Verification Checklist
- Verify the final status of the Separation Agreement after the seven-day revocation period.
- Confirm the appointment of a new Chief Financial Officer to replace Mr. Brenneman.
- Review the full text of the Separation Agreement (Exhibit 10.1) for additional covenants or conditions not summarized in the report.